Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART

Xutao Guo, Yunxia Zhang, Haohao Lei, Yongqiang Wei, Xiaolei Wei, Qi Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 7249.

https://doi.org/10.1182/blood-2024-201948

Published: 2024

Journal Articles

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Shenmiao Yang, Ru Feng, Xutao Guo, Zhenling Li, Qianqian Ju, Yujun Dong, Bingjie Wang, Yu Zhao, Liang Wang, Wanling Sun, Fang Fang, Liru Wang, Liping Su, Xiaojun Huang

Blood (2024) 144 (Supplement 1): 7819.

https://doi.org/10.1182/blood-2024-210572

Published: 2024

Journal Articles

Synergistic Killing Effect and Molecular Mechanism of Dual Targeting of Lymphoma By GSK-3 Inhibitor (9-ING-41) and BCL2 Inhibitor (ABT-199)

Haohao Lei, Yunxia Zhang, Xutao Guo

Blood (2024) 144 (Supplement 1): 5844.

https://doi.org/10.1182/blood-2024-204418

Published: 2024

Journal Articles

Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2024) 144 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2024-197877

Published: 2024

Journal Articles

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Xutao Guo, Xiaolei Wei, Yongqiang Wei, Qi Wei, Ning Su, Yunxia Zhang, Haohao Lei, Ru Feng

Blood (2024) 144 (Supplement 1): 6776.

https://doi.org/10.1182/blood-2024-207666

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 6773.

https://doi.org/10.1182/blood-2024-206560

Published: 2024

Journal Articles

Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial

Xiaolei Wei, Xutao Guo, Qi Wei, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 3121.

https://doi.org/10.1182/blood-2024-204940

Published: 2024

Journal Articles

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Xiaolei Wei, Xutao Guo, Qi Wei, Dan Xiong, Peng Zhang, Zewen Zhang, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2024-204915

Published: 2024

Journal Articles

Curcumin Enhances Ibrutinib Induced Killing Effect Against TP53-Mutated Chronic Lymphocytic Leukemia Cells in Vitro

Yunxia Zhang, Haohao Lei, Xiaolei Wei, Yongqiang Wei, Ru Feng, Xutao Guo

Blood (2023) 142 (Supplement 1): 5792.

https://doi.org/10.1182/blood-2023-179874

Published: 2023

Journal Articles

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Xiaolei Wei, Xutao Guo, Qi Wei, Dan Xiong, Peng Zhang, Zewen Zhang, Yongqiang Wei, Ru Feng

Blood (2023) 142 (Supplement 1): 6223.

https://doi.org/10.1182/blood-2023-182496

Published: 2023

Journal Articles

The Prognostic Value of Dynamic Change of NK-Cell Counts in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Chen Huan, Zhongxin Zheng, Yongqiang Wei, Xutao Guo, Qi Wei, Ru Feng, Xiaolei Wei

Blood (2023) 142 (Supplement 1): 6262.

https://doi.org/10.1182/blood-2023-181412

Published: 2023

Journal Articles

The Efficacy of Plerixafor Plus Recombinant Human Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients with Lymphoma and Plasma Cell Diseases

Xutao Guo, Yongqiang Wei, Xiaolei Wei, Haiqing Zheng, Yunxia Zhang, Haohao Lei, Qi Wei, Qifa Liu, Ru Feng

Blood (2021) 138 (Supplement 1): 4851.

https://doi.org/10.1182/blood-2021-148487

Published: 2021

Journal Articles

HOXA11 Regulates Chemoresistance By Modulating p53 Gene Expression in Acute Myeloid Leukemia

Xutao Guo, MD, Bowen Yan, PhD, Yi Qiu, PhD

Blood (2019) 134 (Supplement_1): 5182.

https://doi.org/10.1182/blood-2019-127542

Published: 2019

Journal Articles

Hematologic Malignancies and Carbapenem Resistance: A Multicentre Retrospective Study from Chinese People

Bing Xu, MD PhD, Suming Huang, PhD, Lingli He, Guoshu Chen, Zhifeng Li, Pengcheng Shi, Xutao Guo, Zhihong Fang, Yan Wang, Jie Li, Yong Zhou

Blood (2017) 130 (Supplement 1): 4826.

https://doi.org/10.1182/blood.V130.Suppl_1.4826.4826

Published: 2017

Journal Articles

Tigecycline Was a Promising Candidate for Febrile Neutropenic and Carbapenem-Resistant Patients with Hematologic Malignancy

Bing Xu, PhD, Lingli He, Pengcheng Shi, Xutao Guo, Jie Li, Yan Wang, Manman Deng, Yong Zhou, Yin Li, Jiabao Liang

Blood (2015) 126 (23): 4610.

https://doi.org/10.1182/blood.V126.23.4610.4610

Published: 2015

Journal Articles

Intrathecal Rituximab for EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement Unresponsive to Intravenous Rituximab-Based Treatments: A Prospective Study

Qifa Liu, MD, Meiqing Wu, Jing Sun, MD, Yu Zhang, MD, Fen Huang, Hongsheng Zhou, Zhiping Fan, Li Xuan, Guopan Yu, Xutao Guo, Min Dai, Ru Feng, MD

Blood (2015) 126 (23): 4352.

https://doi.org/10.1182/blood.V126.23.4352.4352

Published: 2015

Journal Articles

Utility of F-18 FDG PET/CT for the Diagnosis and Therapeutic Management of Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type

Bing Xu, MD, Rongwei Li, Pengcheng Shi, MD, Huijuan Dong, MD, Xutao Guo, MD, Zhiping Fan, Fen Huang, MD

Blood (2014) 124 (21): 1704.

https://doi.org/10.1182/blood.V124.21.1704.1704

Published: 2014

Journal Articles

Sequential Intensified Conditioning Followed By Early Tapering Immunosuppressants and DLI In Allogeneic Hematopoietic Stem Cell Transplantation For Refractory/Recurrent T Lymphoblastic Lymphoma

Min Dai, Hongsheng Zhou, Fen Huang, Yu Zhang, Zhiping Fan, Xutao Guo, M.D., Na Xu, Jing Sun, MD, Qifa Liu, MD

Blood (2013) 122 (21): 2122.

https://doi.org/10.1182/blood.V122.21.2122.2122

Published: 2013

Journal Articles

Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine and Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission

Qifa Liu, MD, Hui Liu, Daihong Liu, Yongrong Lai, MD, Jing Sun, MD, Chaoyang Song, Yu Zhang, Yang Xiao, MD, Fen Huang, MD, Hongsheng Zhou, Zhiping Fan, Xutao Guo, M.D., Danian Nie, MD, Guopan Yu, MD&M Sci, Xiaojun Huang

Blood (2013) 122 (21): 3290.

https://doi.org/10.1182/blood.V122.21.3290.3290

Published: 2013

Journal Articles

HLA Polymorphisms and Epstein-Barr Virus Infection In The Recipient Of Allogeneic Hematopoietic Stem Cell Transplantation

Ren Lin, Qian Fan, Sijian Yu, Zhiping Fan, Yu Zhang, Fen Huang, M.D., Hongsheng Zhou, Li Xuan, Meiqing Wu, Xutao Guo, M.D., Min Dai, PhD, Jing Sun, MD, Qifa Liu, M.D.

Blood (2013) 122 (21): 3291.

https://doi.org/10.1182/blood.V122.21.3291.3291

Published: 2013

NARROW

The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Synergistic Killing Effect and Molecular Mechanism of Dual Targeting of Lymphoma By GSK-3 Inhibitor (9-ING-41) and BCL2 Inhibitor (ABT-199)

Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Curcumin Enhances Ibrutinib Induced Killing Effect Against TP53-Mutated Chronic Lymphocytic Leukemia Cells in Vitro

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

The Prognostic Value of Dynamic Change of NK-Cell Counts in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

The Efficacy of Plerixafor Plus Recombinant Human Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients with Lymphoma and Plasma Cell Diseases

HOXA11 Regulates Chemoresistance By Modulating p53 Gene Expression in Acute Myeloid Leukemia

Hematologic Malignancies and Carbapenem Resistance: A Multicentre Retrospective Study from Chinese People

Tigecycline Was a Promising Candidate for Febrile Neutropenic and Carbapenem-Resistant Patients with Hematologic Malignancy

Intrathecal Rituximab for EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement Unresponsive to Intravenous Rituximab-Based Treatments: A Prospective Study

Utility of F-18 FDG PET/CT for the Diagnosis and Therapeutic Management of Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type

Sequential Intensified Conditioning Followed By Early Tapering Immunosuppressants and DLI In Allogeneic Hematopoietic Stem Cell Transplantation For Refractory/Recurrent T Lymphoblastic Lymphoma

Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine and Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission

HLA Polymorphisms and Epstein-Barr Virus Infection In The Recipient Of Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only